{"id":10517,"date":"2010-06-01T16:31:09","date_gmt":"2010-06-01T16:31:09","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10517"},"modified":"2013-12-06T16:59:30","modified_gmt":"2013-12-06T16:59:30","slug":"raltegravir-and-darunavir-pharmacokinetics-in-liver-disease","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10517","title":{"rendered":"Raltegravir and darunavir pharmacokinetics in liver disease"},"content":{"rendered":"<p><strong>www.hiv-druginteractions.org<\/strong><\/p>\n<p>The pharmacokinetic profiles of darunavir and raltegravir were analysed in five HIV\/HCV coinfected patients with moderate to severe liver disease. Based on the ultrasonographic and histological evaluation, two patients had HCV-related chronic active hepatitis, and three patients had a diagnosis of cirrhosis (Child Pugh stage B). Trough concentrations were determined 14 and 30 days after starting a raltegravir\/darunavir containing regimen.<\/p>\n<p>Mean raltegravir and darunavir trough concentrations in the hepatic impairment group was 637 (mean Ctrough in control group: 221\u00b1217 ng\/ml) and 8519 ng\/mL (mean Ctrough in control group: 3236\u00b12183 ng\/ml), respectively. In a sub-group analysis, patients with cirrhosis had higher mean raltegravir Ctrough than patients with active non cirrhotic hepatitis (665 vs 581 ng\/mL). The mean darunavir Ctrough was consistently higher in cirrhotic than non cirrhotic patients (9820 vs 2016 ng\/mL).<\/p>\n<h2>comment<\/h2>\n<p><strong>The data suggest special caution in the use of raltegravir, and especially of darunavir, in patients with moderate to severe liver impairment because of the risk of additionally increased toxicity.<\/strong><\/p>\n<p>Ref: Tommasi C et al. Raltegravir and darunavir plasma pharmacokinetic in HIV-1 infected patients with advanced liver disease.11th PK Workshop, 2010. Abstract 10.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>www.hiv-druginteractions.org The pharmacokinetic profiles of darunavir and raltegravir were analysed in five HIV\/HCV coinfected patients with moderate to severe liver disease. Based on the ultrasonographic and histological evaluation, two patients had HCV-related chronic active hepatitis, and three patients had a &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[134],"class_list":["post-10517","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-pk-workshop-11th-2010"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10517"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10517\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}